SCHEMBL1203271

SCHEMBL1203271

CCOC(=O)c1cccc(NC(=O)c2cnc3ccc(N(C)Cc4ccc(OC)cc4)nn23)c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.48
▸ MAPT P10636 9/20 0.47
▸ NPC1 O15118 7/20 0.45
▸ RAB9A P51151 7/20 0.45
▸ SMN1; SMN2 Q16637 6/20 0.45
▸ HPGD P15428 1/20 0.45
▸ LMNA P02545 5/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ MAPK1 P28482 2/20 0.44
▸ TP53 P04637 5/20 0.44
▸ MEN1 O00255 3/20 0.43
▸ RXFP1 Q9HBX9 2/20 0.43
▸ TSHR P16473 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ ABCB1 P08183 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ ABCG2 Q9UNQ0 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1203883 0.89 MAPT (0.41) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1203885 0.85 MEN1 (0.39) KMT2AMAPTHPGDLMNAALDH1A1
SCHEMBL1202900 0.85 PPARD (0.46) KMT2AMAPTHPGDLMNAALDH1A1
SCHEMBL1203076 0.84 PIM1 (0.51) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1202443 0.83 KMT2A (0.49) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1202941 0.80 KMT2A (0.47) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1203558 0.80 KDM4E (0.47) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1203223 0.78 KMT2A (0.46) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1204093 0.77 NTRK1 (0.48) KMT2AMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1202379 0.76 NTRK1 (0.47) KMT2AMAPTNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046127-A1 Imidazopyridazines for Use as Protein Kinase Inhibitors CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2011-02-24 — — US disclosed
EP-2217601-A1 IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) 2010-08-18 — — EP disclosed
WO-2009060197-A1 IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2009-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046127-A1 Imidazopyridazines for Use as Protein Kinase Inhibitors PIM1, PIM3, PIM2 KMT2A 1247/4885MAPT 3988/4885NPC1 3092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback